Literature DB >> 23196181

The ribonuclease L-dependent antiviral roles of human 2',5'-oligoadenylate synthetase family members against hepatitis C virus.

Young-Chan Kwon1, Ju-Il Kang, Soon B Hwang, Byung-Yoon Ahn.   

Abstract

The latent ribonuclease RNase L and the interferon-inducible 2',5'-oligoadenylate synthetase (OAS) have been implicated in the antiviral response against hepatitis C virus (HCV). However, the specific roles of these enzymes against HCV have not been fully elucidated. In this study, a scarce endogenous expression and RNA degrading activity of RNase L in human hepatoma Huh7 cells enabled us to demonstrate the antiviral activity of RNase L against HCV replication through the transient expression of the enzyme. The antiviral potential of specific members of the OAS family was further examined through overexpression and RNA interference approaches. Our data suggested that among the members of the OAS family, OAS1 p46 and OAS3 p100 mediate the RNase L-dependent antiviral activity against HCV.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23196181     DOI: 10.1016/j.febslet.2012.11.010

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

Review 1.  Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?

Authors:  Da-Rong Yang; Hai-Zhen Zhu
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

2.  A human cellular noncoding RNA activates the antiviral protein 2'-5'-oligoadenylate synthetase 1.

Authors:  Brenda M Calderon; Graeme L Conn
Journal:  J Biol Chem       Date:  2018-08-20       Impact factor: 5.157

3.  Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.

Authors:  Yanan Zhao; Xuezhi Cao; Mingzhe Guo; Xuesong Wang; Tao Yu; Liqing Ye; Lin Han; Lei Hei; Wanyin Tao; Yimin Tong; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

4.  Hepatitis C Virus. Strategies to Evade Antiviral Responses.

Authors:  Nandan S Gokhale; Christine Vazquez; Stacy M Horner
Journal:  Future Virol       Date:  2014       Impact factor: 1.831

5.  Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.

Authors:  Tapas Patra; Reina Sasaki; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 6.  Evolutionary and population (epi)genetics of immunity to infection.

Authors:  Luis B Barreiro; Lluis Quintana-Murci
Journal:  Hum Genet       Date:  2020-04-13       Impact factor: 4.132

7.  The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.

Authors:  Wenyu Lin; Chuanlong Zhu; Jian Hong; Lei Zhao; Nikolaus Jilg; Dahlene N Fusco; Esperance A Schaefer; Cynthia Brisac; Xiao Liu; Lee F Peng; Qikai Xu; Raymond T Chung
Journal:  J Hepatol       Date:  2014-12-03       Impact factor: 25.083

Review 8.  The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.

Authors:  You Li; Daisuke Yamane; Takahiro Masaki; Stanley M Lemon
Journal:  Nat Rev Microbiol       Date:  2015-08-10       Impact factor: 60.633

9.  Nuclear import sequence identification in hOAS3 protein.

Authors:  Lucia Malaguarnera; Giuseppe Nunnari; Michelino Di Rosa
Journal:  Inflamm Res       Date:  2016-07-05       Impact factor: 4.575

10.  Mutual antagonism between circadian protein period 2 and hepatitis C virus replication in hepatocytes.

Authors:  Giorgia Benegiamo; Gianluigi Mazzoccoli; Francesco Cappello; Francesca Rappa; Nunzia Scibetta; Jude Oben; Azzura Greco; Roger Williams; Angelo Andriulli; Manlio Vinciguerra; Valerio Pazienza
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.